Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal (Q40380970)

20 September 2017

Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal (English)

1 reference

20 September 2017

0 references

visceral leishmaniasis

1 reference

M Boelaert

8

0 references

author name string

S Rijal

1

1 reference

20 September 2017

S Bhandari

2

1 reference

20 September 2017

S Koirala

3

1 reference

20 September 2017

R Singh

4

1 reference

20 September 2017

B Khanal

5

1 reference

20 September 2017

L Loutan

6

1 reference

20 September 2017

J C Dujardin

7

1 reference

20 September 2017

F Chappuis

9

1 reference

20 September 2017

1 September 2009

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

20 September 2017

1 reference

20 September 2017

104

1 reference

20 September 2017

3

1 reference

20 September 2017

225-229

1 reference

The world's most neglected diseases

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Drug resistance in Indian visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

The economic impact of visceral leishmaniasis on households in Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Clinicoepidemiological study of drug resistance in Indian kala-azar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Sodium stibogluconate cardiotoxicity and safety of generics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

The relationship between leishmaniasis and AIDS: the second 10 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Oral miltefosine for Indian visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Injectable paromomycin for Visceral leishmaniasis in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Chemotherapy in the treatment and control of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Laboratory testing and rapid HIV assays: applications for HIV surveillance in hard-to-reach populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Socio-economics of visceral leishmaniasis in Bihar (India)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

The economic burden of visceral leishmaniasis for households in Nepal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Visceral leishmaniasis control: a public health perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

Leishmaniasis: current situation and new perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2009.08.002

10.1016/J.TRSTMH.2009.08.002

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference